ATS 2019 Virtual Final Program

P456 Rapidly Evolving Pulmonary Granulomas: A NOD2 Home Genetic Testing/ D.K. Zielke, G. Atkins, Lebanon, NH, p.A4584 P457 I am Everywhere - Sarcoidosis in the Iliac Bone; Is It Osseous Sarcoidosis or Osseous Metastasis?/ S. Habib, M. Azam, A.H. Siddiqui, K. Rajdev, M. Chalhoub, Staten Island, NY, p.A4585 P458 Alveolar Hemorrhage as the Presenting Manifestation of Systemic Lupus Erythematosus/ R. Mangat, G. Johri, Syracuse, NY, p.A4586 P459 PR3-ANCA Associated Microscopic Polyangiitis as a Manifestation of Pulmonary Renal Syndrome/ S. Hart, C. Damiano, Wynnewood, PA, p.A4587 P460 Mistaken Identity - Right Treatment for Wrong Disease/ D. Gandhiraj, G. Kamel, S. Osmon, St. Louis, MO, p.A4588 P461 Don’t Stop Anticoagulation - Recurrent Pulmonary Embolism in a Patient with Granulomatosis with Polyangiitis/ M. Garcia, J.V.G. Costa, T.V. Pereira, C.G. Rodrigues, C.S.V. Barbas, Sao Paulo, Brazil, p.A4589 P462 Hereditary Angioedema Types I, II, and III in a Woman Whose Sibling Had Throat Closure and Premature Death/ A. Pagnotta, A.M. Szema, South Setauket, NY, p.A4590 P463 Kaposi’s Sarcoma-Associated Herpesvirus Inflammatory Cytokine Syndrome - Diagnostic and Management Dilemmas in the Critically Ill Patient with KICS/ M.P. Clark-Coller, B.T. Kuhn, H.H. Rashidi, M.V. Avdalovic, Sacramento, CA, p.A4591 BASIC • CLINICAL • TRANSLATIONAL THEMATIC POSTER SESSION C34 ILD AND IPF: CLINICAL AND MECHANISTIC STUDIES 9:15 a.m. - 4:15 p.m. KBHCCD Area H (Hall F, Level 2) Viewing: Posters will be on display for entire session. Discussion: 11:15-12:00: authors will be present for individual discussion 12:00-1:00: authors will be present for discussion with assigned facilitators. Facilitator : B.B. Moore, PhD, ATSF, Ann Arbor, MI P1031 Chronic Obstructive Pulmonary Disease and Idiopathic Pulmonary Fibrosis Mechanism Comparison on the Basis of Gene Expression Profiles/ F. Xu, N. Tanabe, D. Kinose, D.M. Vasilescu, J.E. McDonough, K. Ikezoe, K. Ng, S. Verleden, B. Vanaudenaerde, J. Verschakelen, J.D. Cooper, M.E. Lenburg, A. Spira, J.C. Hogg, Vancouver, Canada, p.A4592 P1032 Time of Intervention Affects Anti-PD-L1 Reduction in Pulmonary Fibrosis/ K. Abel, N. Hassell, W. Luo, W.P. Drake, O.S. Chioma, Nashville, TN, p.A4593 P1033 Importance of Interleukin-23 to the Development of Acute Exacerbation in Pulmonary Fibrosis/ S. Senoo, A. Taniguchi, J. Itano, N. Oda, D. Morichika, A. Yoshimura, A. Kanehiro, K. Kiura, Y. Maeda, N. Miyahara, Okayama, Japan, p.A4594 P1034 Potential Clinical Utility of MUC5B and TOLLIP Single Nucleotide Polymorphisms (SNP) in the Management of Patients with IPF: Preliminary Results/ F. Bonella, I. Campo, E. Boerner, D. Theegarten, J. Guzman, U. Costabel, Essen, Germany, p.A4595 P1035 Antinuclear Antibodies in Patients with Hypersensitivity Pneumonitis: Insights on Clinical Relevance from a German Double-Cohort Investigation/ F. Bonella, U. Costabel, M. Joest, M. Rolke, J. Sennekamp, D. Koschel, Essen, Germany, p.A4596 P1036 Rationale, Design and Objectives of Two Phase III, Randomised, Placebo-Controlled Studies of GLPG1690, a Novel Autotaxin Inhibitor, in Idiopathic Pulmonary Fibrosis (ISABELA 1 and 2)/ T.M. Maher, M. Kreuter, D.J. Lederer, K.K. Brown, W. Wuyts, N. Verbruggen, S. Stutvoet, A. Fieuw, P. Ford, W. Abi-Saab, M. Wijsenbeek, London, United Kingdom, p.A4597 P1037 Staphylococcal Pneumonia Impacts Disease Outcome in Pulmonary Fibrosis/ H. Warheit-Niemi, D. O’Dwyer, B.B. Moore, Ann Arbor, MI, p.A4598 P1038 HLA DRB1*04 Increase the Risk to Develop Interstitial Lung Abnormalities (ILA) in Older Individuals/ N.J. Cortez, R. Falfan-Valencia, D.A.-P. Alma, A.-O. Enrique, G. Perez-Rubio, M. Mayra, A. Estrada, I. Buendia-Roldan, Mexico, Mexico, p.A4599 P1039 The Effect of Nintedanib on T Cell Activation, Subsets and Functions/ K. Ubieta-Hernandez, S.-L. Wollin, M.J. Thomas, Biberach an der Riss, Germany, p.A4600 P1040 Evaluation of HRCT-Derived Quantitative Lung Fibrosis (QLF) Scores in an 8-Week Phase 2a Study for Treatment of Idiopathic Pulmonary Fibrosis (IPF) Using BG00011/ J. Goldin, P. Bansal, R. Raj, M. Arefayene, J. Liu, C. Stebbins, G. Zhao, G. Song, G.H. Kim, R. Christmann de Souza, S.M. Violette, G. Raghu, M. Mouded, F. Martinez, D.C. Gallagher, Santa Monica, CA, p.A4601 Facilitator : R.S. Knipe, MD, Boston, MA P1041 Environmental Exposure to Cadmium and Lung Fibrosis/ F.J. Li, R. Surolia, H. Li, Z. Wang, G. Liu, A.V.F. Massicano, J.A. de Andrade, T. Kulkarni, K.M. Wille, M. Athar, S.E. Lapi, V.J. Thannickal, A.B. Carter, V.B. Antony, Birmingham, AL, p.A4602 P1042 Attenuated Pulmonary Fibrosis in Sialidase-3 Knockout (Neu3-/-) Mice/ T.R. Karhadkar, D. Pilling, R.H. Gomer, College Station, TX, p.A4603 P1043 Inhibiting Prostaglandin E2 Degradation Is Protective in a Mouse Model of Pulmonary Fibrosis/ T. Baernthaler, A. Theiler, I. Lanz, D. Thomas, K. Jandl, G. Kwapiszewska, R. Schuligoi, A. Heinemann, Graz, Austria, p.A4604 P1044 Pulmonary Delivery of NLRP3 Antisense Oligonucleotides Are Effective at Preventing but Not Reversing Established Bleomycin-Induced Pulmonary Fibrosis in Mice/ D. Bai, Carlsbad, CA, p.A4605 P1045 Basophil Depletion Leads to Promotion of the Lung Fibrosis in Bleomycin-Mouse Model/ T. Tateishi, S. Shibata, H. Karasuyama, Y. Miyazaki, Tokyo, Japan, p.A4606 ATS 2019 • Dallas, TX 244 TUESDAY • MAY 21